{"disease":{"id":"cholestatic-pruritus-in-pfic","name":"cholestatic pruritus in pfic"},"drugs":{"marketed":[{"drug_id":"maralixibat-hydrochloride","indication_name":"Cholestatic pruritus in PFIC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livmarli","generic_name":"maralixibat hydrochloride","company_name":"Mirum Pharma Inc","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor","quality_score":57,"revenue":null,"mechanism":"Livmarli works by blocking the ileal sodium/bile acid cotransporter, which reduces the amount of bile acids reabsorbed into the bloodstream."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}